

Dolan Sondhi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3457684/publications.pdf>

Version: 2024-02-01

37
papers

1,838
citations

331670

21
h-index

330143

37
g-index

37
all docs

37
docs citations

37
times ranked

1984
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis by CNS Administration of a Serotype 2 Adeno-Associated Virus Expressing CLN2 cDNA. <i>Human Gene Therapy</i> , 2008, 19, 463-474.	2.7	366
2	Enhanced Survival of the LINCL Mouse Following CLN2 Gene Transfer Using the rh.10 Rhesus Macaque-derived Adeno-associated Virus Vector. <i>Molecular Therapy</i> , 2007, 15, 481-491.	8.2	153
3	Administration of a Replication-Deficient Adeno-Associated Virus Gene Transfer Vector Expressing the Human CLN2 cDNA to the Brain of Children with Late Infantile Neuronal Ceroid Lipofuscinosis. <i>Human Gene Therapy</i> , 2004, 15, 1131-1154.	2.7	118
4	AAVrh.10-Mediated APOE2 Central Nervous System Gene Therapy for APOE4-Associated Alzheimer's Disease. <i>Human Gene Therapy Clinical Development</i> , 2018, 29, 24-47.	3.1	90
5	Long-Term Expression and Safety of Administration of AAVrh.10hCLN2 to the Brain of Rats and Nonhuman Primates for the Treatment of Late Infantile Neuronal Ceroid Lipofuscinosis. <i>Human Gene Therapy Methods</i> , 2012, 23, 324-335.	2.1	84
6	Disease characteristics and progression in patients with late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2) disease: an observational cohort study. <i>The Lancet Child and Adolescent Health</i> , 2018, 2, 582-590.	5.6	84
7	Intra-arterial delivery of AAV vectors to the mouse brain after mannitol mediated blood brain barrier disruption. <i>Journal of Controlled Release</i> , 2014, 196, 71-78.	9.9	70
8	Intracerebral Gene Therapy Using AAVrh.10-hARSA Recombinant Vector to Treat Patients with Early-Onset Forms of Metachromatic Leukodystrophy: Preclinical Feasibility and Safety Assessments in Nonhuman Primates. <i>Human Gene Therapy Clinical Development</i> , 2015, 26, 113-124.	3.1	68
9	Gene therapy for metachromatic leukodystrophy. <i>Journal of Neuroscience Research</i> , 2016, 94, 1169-1179.	2.9	64
10	Gene therapy for late infantile neuronal ceroid lipofuscinosis: neurosurgical considerations. <i>Journal of Neurosurgery: Pediatrics</i> , 2010, 6, 115-122.	1.3	60
11	Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis. <i>Experimental Neurology</i> , 2008, 213, 18-27.	4.1	59
12	Intracerebral adeno-associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. <i>Neurobiology of Aging</i> , 2016, 44, 159-172.	3.1	59
13	Vectored Intracerebral Immunization with the Anti-Tau Monoclonal Antibody PHF1 Markedly Reduces Tau Pathology in Mutant Tau Transgenic Mice. <i>Journal of Neuroscience</i> , 2016, 36, 12425-12435.	3.6	53
14	Partial Correction of the CNS Lysosomal Storage Defect in a Mouse Model of Juvenile Neuronal Ceroid Lipofuscinosis by Neonatal CNS Administration of an Adeno-Associated Virus Serotype rh.10 Vector Expressing the Human CLN3 Gene. <i>Human Gene Therapy</i> , 2014, 25, 223-239.	2.7	37
15	Genetic Modification of the Lung Directed Toward Treatment of Human Disease. <i>Human Gene Therapy</i> , 2017, 28, 3-84.	2.7	37
16	Spectrum of Ocular Manifestations in Δ CLN2-Associated Batten (Jansky-Bielschowsky) Δ Disease Correlate with Advancing Age and Deteriorating Neurological Function. <i>PLoS ONE</i> , 2013, 8, e73128.	2.5	36
17	Slowing late infantile Batten disease by direct brain parenchymal administration of a rh.10 adeno-associated virus expressing CLN2. <i>Science Translational Medicine</i> , 2020, 12, .	12.4	35
18	Feasibility of Gene Therapy for Late Neuronal Ceroid Lipofuscinosis. <i>Archives of Neurology</i> , 2001, 58, 1793.	4.5	33

#	ARTICLE	IF	CITATIONS
19	Anti-hIgE gene therapy of peanut-induced anaphylaxis in a humanized murine model of peanut allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 1652-1662.e7.	2.9	33
20	Gene therapy for C1 esterase inhibitor deficiency in a Murine Model of Hereditary angioedema. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1081-1089.	5.7	31
21	Biology of the Adrenal Gland Cortex Obviates Effective Use of Adeno-Associated Virus Vectors to Treat Hereditary Adrenal Disorders. <i>Human Gene Therapy</i> , 2018, 29, 403-412.	2.7	29
22	Stress-Induced Mouse Model of the Cardiac Manifestations of Friedreich's Ataxia Corrected by AAV-mediated Gene Therapy. <i>Human Gene Therapy</i> , 2020, 31, 819-827.	2.7	23
23	Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). <i>Scientific Reports</i> , 2018, 8, 15229.	3.3	21
24	Advances in the treatment of neuronal ceroid lipofuscinosis. <i>Expert Opinion on Orphan Drugs</i> , 2019, 7, 473-500.	0.8	20
25	Brain Region-Specific Degeneration with Disease Progression in Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2 Disease). <i>American Journal of Neuroradiology</i> , 2016, 37, 1160-1169.	2.4	19
26	Anti-Epidermal Growth Factor Receptor Gene Therapy for Glioblastoma. <i>PLoS ONE</i> , 2016, 11, e0162978.	2.5	19
27	<i>In Vivo</i> Potency Assay for Adeno-Associated Virus-Based Gene Therapy Vectors Using AAVrh.10 as an Example. <i>Human Gene Therapy Methods</i> , 2018, 29, 146-155.	2.1	18
28	Safety of Direct Intraparenchymal AAVrh.10-Mediated Central Nervous System Gene Therapy for Metachromatic Leukodystrophy. <i>Human Gene Therapy</i> , 2021, 32, 563-580.	2.7	18
29	Cocaine vaccine dAd5GNE protects against moderate daily and high-dose binge-cocaine use. <i>PLoS ONE</i> , 2020, 15, e0239780.	2.5	18
30	Attenuation of the Niemann-Pick type C2 disease phenotype by intracisternal administration of an AAVrh.10 vector expressing Npc2. <i>Experimental Neurology</i> , 2018, 306, 22-33.	4.1	16
31	Symmetric Age Association of Retinal Degeneration in Patients with CLN2-Associated Batten Disease. <i>Ophthalmology Retina</i> , 2020, 4, 728-736.	2.4	14
32	Intrapleural Gene Therapy for Alpha-1 Antitrypsin Deficiency-Related Lung Disease. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2018, 5, 244-257.	0.7	14
33	Anti-Phospho-Tau Gene Therapy for Chronic Traumatic Encephalopathy. <i>Human Gene Therapy</i> , 2020, 31, 57-69.	2.7	13
34	Cannulation of the internal carotid artery in mice: A novel technique for intra-arterial delivery of therapeutics. <i>Journal of Neuroscience Methods</i> , 2014, 222, 106-110.	2.5	11
35	Long-term functional correction of cystathionine β -synthase deficiency in mice by adeno-associated viral gene therapy. <i>Journal of Inherited Metabolic Disease</i> , 2021, 44, 1382-1392.	3.6	7
36	Advances in the treatment of neuronal ceroid lipofuscinosis. <i>Expert Opinion on Orphan Drugs</i> , 2013, 1, 951-975.	0.8	6

#	ARTICLE	IF	CITATIONS
37	Automated Retinal Layer Segmentation in <i>CLN2</i> -Associated Disease: Commercially Available Software Characterizing a Progressive Maculopathy. <i>Translational Vision Science and Technology</i> , 2021, 10, 23.	2.2	2